![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Department of Pediatrics, Brown University School of Medicine, Providence, Rhode Island (T.Z.); Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, and Drexel University College of Medicine, Philadelphia, Pennsylvania (P.P., S.B., H.B., I.P., R.P.S.); and Department of Molecular and Cellular Cardiology, University of Medicine and Dentistry of New Jersey, Newark, New Jersey (Y.-T.S.)
Received for publication
January 4, 2006
Accepted
February 8, 2006.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
; Kieffer and Habener, 1999; Doyle and Egan, 2001). GLP-1 has insulinotropic, insulinomimetic, and glucagonostatic effects, thereby exerting multiple complementary actions to lower blood glucose in subjects with type 2 diabetes mellitus (Drucker, 1998; Kieffer and Habener, 1999; Doyle and Egan, 2001). A major advantage over conventional insulin is the fact that the insulinotropic actions of GLP-1 are dependent on the ambient glucose concentration, mitigating the risks of hypoglycemia.
Although receptors for GLP-1 have been found in a variety of extrapancreatic tissues including the heart (Bullock et al., 1996; Wei and Mojsov, 1996), whether there are direct cardiovascular actions of GLP-1 remains controversial. For example, GLP-1 increased heart rate and blood pressure in intact rodents through sympathostimulatory effects (Barragan et al., 1994, 1996; Yamamoto et al., 2002) but depressed myocardial contractility in isolated rat ventricular myocytes (Vila Petroff et al., 2001). Recently, infusion of GLP-1 was associated with improvements in myocardial glucose uptake and left ventricular (LV) systolic function in conscious dogs with dilated cardiomyopathy but not in normal dogs (Nikolaidis et al., 2004a). Our laboratory has also shown that GLP-1 infusion improved regional and global function in patients with myocardial infarction and severe LV systolic dysfunction after successful primary angioplasty (Nikolaidis et al., 2004b). However, neither hemodynamics nor consequent infarct size was altered by GLP-1 infusion in an openchest, anesthetized porcine model of ischemia (Kavianipour et al., 2003). By contrast, GLP-1 infusion reduced infarct size in an isolated isovolumic rodent model of regional ischemia, but ventricular function was unaffected and glucose uptake was not measured (Bose et al., 2005). As such, whether the actions of GLP-1 on myocardial function and glucose uptake are mediated by direct effects and whether they are evident in both normal and ischemic myocardium remain unresolved.
Accordingly, the purpose of the present study was to determine whether GLP-1 had direct effects on myocardial contractility and glucose uptake in the isovolumic rat heart. A second goal was to examine the cellular effects of GLP-1 on the translocation of glucose transport proteins. A third goal was to compare these effects with those observed after 30 min of low-flow global ischemia and to determine whether GLP-1 hastened the recovery of ventricular function during reperfusion.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
The methodology of Langendorff-perfused rat heart preparation has been described previously in details (Zhao et al., 2001). Briefly, hearts were cannulated via ascending aorta for retrograde perfusion at 37°C under constant pressure (70 mm Hg) using KH buffer containing 119 mM NaCI, 5.4 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3, 0.25 mM EDTA, and 5.0 mM glucose. All buffer components were obtained from Sigma Chemical (St. Louis, MO). A left atrial incision was made to expose the mitral annulus through which a water-filled latex balloon was passed into the left ventricle. The balloon was attached via polyethylene tubing to a pressure transducer (model Px 272; Baxter Scientific Products, Miami, FL) that was connected to Triton System I. The initial balloon volume was set to generate left ventricular enddiastolic pressure (LVEDP) 
5 mm Hg. Myocardial function was measured, including left ventricular developed pressure (LVDevP), LVEDP, and LV dP/dt. LVDevP was calculated by subtracting LVEDP from the peak systolic pressure. Coronary flow was calculated by a timed collection of the effluent.
The perfusate leaving the heart was collected over 1 min for the measurement of glucose and lactate during steady state every 10 to 15 min during the respective protocols. Glucose and lactate in perfusate was measured using a YSI glucose analyzer. Glucose uptake was calculated by the following equation (Tada et al., 2000): Myocardial glucose uptake (micromoles per minute per gram) = [Gin – Gout] x coronary flow rate (milliliters per minute)/gram dry weight where Gin is glucose concentration (inflow) and Gout is glucose concentration (outflow). Myocardial lactate production (micromoles per minute per gram) was measured as the product of (Lacout – Lacin) and coronary flow rate (milliliters per minute)/gram dry weight.
Experimental Protocols
Experimental Protocol 1. After a 30-min period of stabilization with KH buffer, hearts were randomly divided into three groups: 1) control group (n = 15), hearts were continuously perfused with KH buffer for an additional 30 min; 2) GLP-1 group (n = 15), hearts were switched into KH buffer containing GLP-1 (500 pmol/l) for an additional 30 min; 3) insulin group (n = 15), hearts were switched into to KH buffer containing insulin (100 µU/ml) for an additional 30 min. GLP-1-(7–36) amide was synthesized in the protein/peptide core facility of the Endocrine Unit of the Massachusetts General Hospital. The peptide content was 99% pure and gave a single peak on high-performance liquid chromatography. The peptide was lyophilized in vials under sterile conditions for single use and was certified to be both pyrogen-free and sterile. Net peptide content was used for all calculations. The peptide used in this protocol was from a single lot. Novolin U-100 insulin was purchased from NovoNordisk (Princeton, NJ).
Experimental Protocol 2. The goal of these experiments was to determine whether GLP-1 mitigates postischemic contractile dysfunction after brief periods of low-flow ischemia. After 30 min of perfusion with normal KH buffer, hearts were subjected to low-flow global ischemia (5% of baseline flow by reducing coronary perfusion pressure to 25–30 mm Hg) for 30 min followed by 30 min of reperfusion. The control group (n = 10) received KH buffer during low-flow ischemia and recovery; The GLP-1 treatment group (n = 10) received KH buffer plus GLP-1 (500 pmol/l), administrated 1 min before induction of low-flow ischemia and throughout reperfusion. To compare the direct effects of GLP-1 to insulin on postischemic contractile dysfunction, a third group (n = 10) was studied in which insulin (100 µU/ml) was added 1 min before the induction of low-flow ischemia and throughout reperfusion. Ventricular function, myocardial glucose uptake, and lactate production were measured every 10 to 15 min during the protocol. Creatine phosphokinase levels were measured on effluent collected at 20 min of reperfusion.
Myocardial Insulin Signaling Cascade
LV myocardium from 10 control, 10 GLP-1-treated, and 10 insulin-treated hearts from protocol 1 and seven control, eight GLP-1-treated, and eight insulin-treated hearts from protocol 2 were snap-frozen in liquid nitrogen and stored at –70°C. Purified sarcolemmal membranes were prepared using density gradient centrifugation as described previously (Nikolaidis et al., 2004c). Translocation of respective GLUT transporters (GLUT-1 and GLUT-4) was analyzed by assessing the protein content in the purified sarcolemmal membrane preparations as a percentage of the total protein expression in the sarcolemma and cytosolic membrane fractions under the respective experimental circumstances.
LV myocardium was homogenized in a buffer free of phosphatase inhibitors and subjected to electrophoresis separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Nikolaidis et al., 2004c). Resolved proteins were transferred onto a polyvinylidene difluoride membrane (Immobilon-PSQ; Millipore Corp., Bedford, MA) at a constant voltage (100 V) for 1 to 2 h at 4°C. Nonspecific membrane protein binding sites were blocked for at least 1 h at room temperature, and then membranes were probed with the specific primary antibody overnight at 4°C. The blots were washed in appropriate secondary antibody-horseradish peroxidase conjugate. The immunoreactive proteins were detected by use of an enhanced horseradish peroxidase/luminol chemiluminescence reaction kit (NEN Life Science Products, Boston, MA) and exposed to X-ray film (Hyperfilm ECL; Amersham Pharmacia Biotech, Piscataway, NJ). Densitometric analysis of the bands was carried out using a Personal Densitometer SI and ImageQuant Software (Molecular Dynamics, Sunnyvale, CA). Adjustments for protein loading were accomplished by normalizing bands based upon Coomassie Blue staining of the blots.
Goat anti-rabbit IgG-horseradish peroxidase conjugate, anti-Akt-1, anti-phospho-Akt-1 (Ser-473) and (Thr-308) were purchased from BD Transduction Laboratories (San Diego, CA). Anti-GLUT4, anti-GLUT-1, and protein A/G PLUS-agarose were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Phospho-Akt-1 specificity was confirmed using phosphorylated and nonphosphorylated NIH/3T3 cell extracts purchased from Cell Signaling Technology, Inc. (Beverly, MA). Anti-GLP-1 receptor antibody was purchased from Alpha Diagnostics International (San Antonio, TX).
The AMP-activated protein kinase activity in the LV myocardium was determined using the method of Musi et al. (2001). In brief, the LV lysates containing 200 µg of protein were immunoprecipitated with a specific antibody to AMP-activated protein kinase 
2 and protein A/G PLUS-agarose beads. Kinase reactions were performed in 40 mM HEPES, pH 7.0, 0.2 mM AMP, 80 mM NaCl, 0.8 mM dithiothreitol, 5 mM MgCl2, 0.2 mM ATP (containing 2 µCi of 
-[32P]ATP), and 0.2 mM substrate for AMP-activated protein kinase peptide in a final volume of 40 µl for 20 min at 30°C. At the end of the reaction, a 20-µl aliquot was removed and spotted on Whatman P81 paper. Radioactivity was quantitated with a scintillation counter. Activity was expressed as incorporated ATP (picomoles) per milligram of protein per minute.
The p38 MAP kinase activity in the LV myocardium was determined using a p38/SAPK2a assay kit purchased from Upstate Biotechnology (Charlottesville, VA) with slight modifications. In brief, the LV lysates containing 200 µg of protein were immunoprecipitated with a specific antibody to p38 MAPK (Chemicon, Temecula, CA) and protein A/G PLUS-agarose beads. The activation of MAPKAP kinase 2 was carried out by adding 5 µl (200 ng) of unactive MAPKAP kinase 2 and then 5 µl of ice-cold 200 µM ATP-30 mM MgCl2 in assay dilution buffer 1 and incubating for 15 min at 30°C. The activation reaction was stopped by adding 40 µl of ice-cold ADB1 and 10 µl of 0.086 mM MAPKAP 2 kinase substrate peptide. The phosphorylation of MAPKAP kinase 2 substrate peptide was performed by adding 10 µl of 75 mM MgCl2 and 500 µM ATP (containing 5 µCi of -[32P]ATP) in a final volume of 80 µl for 10 min at 30°C. At the end of the reaction, a 20-µl aliquot was removed and spotted on Whatman P81 paper. The papers were washed three times in 1% phosphoric acid and one time with acetone. Radioactivity was quantitated with a scintillation counter. Activity was expressed as incorporated ATP (picomoles) per milligram of protein per minute.
Total nitric oxide production in the isolated preparation was determined by measuring NOx in the effluent after control, GLP-1, and insulin infusions, respectively. The measurements of total nitric oxide (NO) levels were carried out using a kit purchased from R&D Systems, Inc. (Minneapolis, MN). The reaction buffer was ultrafiltered through a 10,000 molecular weight cutoff filter to eliminate proteins. Because most of the NO is oxidized to nitrite and nitrate, the concentrations of these anions are used as a quantitative measurement of NO production. After the enzymatic conversion of nitrate to nitrite by nitrate reductase, the spectrophotometric measurement at 540 nm of nitrite is accomplished by using the Greiss reaction. Standard curves of known nitrite levels were used, and total NO values of experimental samples were determined using a linear curve-fit analysis.
Statistics
All measurements are expressed as means ± S.E.M. The data were analyzed by either unpaired Student's t test or one-way analysis of variance. The Student-Newman-Keuls post hoc test was further used for pairwise comparisons after analysis of variance demonstrated a significant difference between groups. A paired t test was used to compare any pair of pre- and post-treatment values for the same parameter. p < 0.05 was considered significant.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
|
To compare the effects of GLP-1 to insulin, we studied a third group using a similar protocol, but added insulin (100 µU/ml) instead of GLP-1 at 30 min. There was a significant increase in LVDevP (baseline: 98 ± 3 mm Hg; insulin: 108 ± 3 mm Hg; p < 0.05) and LV dP/dtmax (baseline: 4981 ± 98 mm Hg/s; insulin: 5101 ± 78 mm Hg/s; p < 0.05) in contrast to the findings with GLP-1 (Fig. 1). Additionally, insulin administration increased coronary flow (baseline: 14 ± 3; insulin: 19 ± 2 ml/min; p < 0.05) but did not change LVEDP or heart rate (Fig. 1).
Both GLP-1 and insulin administration increased myocardial glucose uptake compared with control (Fig. 2). The increase in glucose uptake was associated with increased glucose extraction and was greater than the observed increase in coronary flow. The increase in myocardial glucose uptake was accompanied by increased myocardial lactate production compared with control, although the magnitude of lactate production was less and occurred later than the increase in glucose uptake.
|
|
The Effect of GLP-1 on Left Ventricular Function during Low-Flow Ischemia. GLP-1 significantly improved the recovery of function after 30 min of low-flow ischemia (Fig. 4). LVDevP (control: 66 ± 6; GLP-1: 84 ± 5; p < 0.05) and LV dP/dtmax (control: 2345 ± 112 mm Hg/s; GLP-1: 4081 ± 165 mm Hg/s; p < 0.05) recovered faster and to a greater extent than control. GLP-1 treatment was associated with a lower postischemic LVEDP (control: 13 ± 4 mm Hg; GLP-1: 4 ± 2mmHg; p < 0.05). Heart rate and coronary flow responses did not change significantly with GLP-1 administration. The effects of GLP-1 did not differ significantly from the effects of insulin on the recovery of LV function after ischemia.
|
|
The Effects of GLP-1 on Postischemic GLUT Translocation. Figure 6 illustrates the effects of GLP-1 on GLUT-1 and GLUT-4 translocation after 30 min of reperfusion compared with insulin or control. There was no difference in AMP kinase activity among the groups (control: 26 ± 5 pmol ATP/mg/min; GLP-1: 28 ± 7 pmol ATP/mg/min; insulin: 31 ± 10 pmol ATP/mg/min), although activity was higher (p < 0.05) in the postischemic myocardium compared with normal hearts (control: 13 ± 5 pmol ATP/mg/min; GLP-1: 17 ± 8 pmol ATP/mg/min; insulin: 15 ± 7 pmol ATP/mg/min). Notably, both the GLP-1- and insulin-treated groups demonstrated increased GLUT-4 and GLUT-1 translocation compared with control but in the absence of increased Akt-1 expression or activation. However, both GLP-1- and insulin-treated groups showed increased myocardial NO production and increased p38 MAP kinase activity in contrast to the selective effects on glucose transporters observed in normal hearts.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
There have been a limited number of studies examining the effects of GLP-1 on infarct size or recovery from a postischemic injury with conflicting results. Kavianipour et al. (2003) reported that GLP-1-(7–36) did not alter myocardial glucose utilization, hemodynamics, or infarct size in an acute porcine model of infarction, despite the fact that GLP-1 increased insulin secretion and decreased lactate uptake. In contrast, our laboratory (Nikolaidis et al., 2005) has demonstrated that a 24-h infusion of GLP-1 (2.5 pmol/kg/min) mitigated postischemic contractile dysfunction and improved ventricular relaxation in conscious dogs after brief periods (10 min) of complete coronary artery occlusion. Similar beneficial effects have been observed in humans treated with a 72-h infusion of a similar dose of GLP-1 after acute myocardial infarction complicated by cardiogenic shock (Nikolaidis et al., 2004b). Nonetheless, these studies do not address whether the effects of GLP-1 were attributable to direct myocardial actions or indirect effects associated with the systemic insulinotropic actions of GLP-1.
Bose et al. (2005) investigated the effects of GLP-1 infusion (4.8 pmol/kg/min) in vitro in Sprague-Dawley rats subjected to 30 min of left anterior descending artery occlusion and 120 min of reperfusion and observed that GLP-1 had no salutary effects on hemodynamics. The absence of hemodynamic benefits was surprising given that the investigators found a 50% reduction in infarct size in the GLP-1-treated group. A major difference between our findings and those of Bose et al. (2005) in the isolated heart models during ischemia may relate to the difference between complete and partial ischemia in the two models. The low-flow global ischemia used in our model may have facilitated GLP-1 perfusion into the ischemic zone, whereas Bose et al. (2005) used a model of complete coronary artery occlusion. Although the results differ, both studies support a direct effect of GLP-1 on myocardial function and preservation.
We observed abundant expression of GLP-1 receptors in the rat myocardium. However, the mechanisms whereby GLP-1 receptors couple to intracellular effectors in extrapancreatic tissues, such as the heart, remain largely unexplored. We observed opposing effects of GLP-1 and insulin on myocardial contractility in normal hearts. In turn, we observed that GLP-1 and insulin had comparable effects on myocardial glucose uptake, but via different cellular mechanisms. Insulin-mediated glucose uptake was associated with Akt-1 phosphorylation and GLUT-4 translocation. In contrast, GLP-1 did not increase phospho-Akt-1 or GLUT-4 translocation but did result in increased GLUT-1 expression in the sarcolemma. Furthermore, GLP-1 was associated with increased myocardial NO production and increased p38 MAP kinase activity. Prior studies have demonstrated that GLP-1 increases NO production in vascular smooth muscle (Nystrom et al., 2004, 2005). However, this is the first illustration of such an effect in myocardium. Importantly, NO has been shown to stimulate p38 MAP kinase (McFalls et al., 2004), and both NO (Van Dyke et al., 2003) and p38 MAP kinase (Denton and Tavare, 1995; Taha et al., 1997) have been shown to increase membrane-associated GLUT-1 in isolated muscle cells. It remains to be determined what the proximal steps are in GLP-1 receptor coupling in the myocardium and where the contractile and glucoregulatory pathways diverge.
During recovery from low-flow ischemia, we showed that both GLP-1 and insulin had comparable effects on myocardial glucose uptake and functional recovery from the ischemic insult. Notably, both GLP-1- and insulin-mediated myocardial glucose uptake did not involve Akt-1 activation in the postischemic myocardium. Our findings on the effects of GLP-1 on Akt-1 activation differ from those reported by Bose et al. (2005). Prior studies (Young et al., 1997; Egert et al., 1999) have shown that low-flow ischemia is associated with increased myocardial GLUT-1 and GLUT-4 expression. Notably, during recovery, all three groups had increased AMP kinase activity consistent with ATP depletion during low-flow ischemia. Although AMP kinase is a potent stimulus to insulin-independent GLUT-4 translocation, this mechanism is insufficient to explain the increases in membrane GLUT-1 expression in the GLP-1- and insulin-treated groups. However, both GLP-1- and insulin-treated groups demonstrated increased NO production and p38 MAP kinase activity in the postischemic hearts compared with control and in contrast to what was observed with insulin in the normal heart. This pathway has been demonstrated previously to be integral to postischemic functional recovery (McFalls et al., 2004). It remains to be elucidated as to how GLP-1 increases nitric oxide production, the isoforms involved, and the intracellular compartment in which nitric oxide synthase is activated. Finally, it is conceivable that the benefits of GLP-1 and insulin to improve postischemic contractile dysfunction are related simply to enhanced glucose uptake rather than to a direct cellular effect on myocardial stunning. Our findings provide new insights into the direct myocardial effects of GLP-1 and novel signaling mechanisms for glucose uptake, independent of the Akt-1 activation.
|
Footnotes |
|---|
ABBREVIATIONS: GLP-1, glucagon-like peptide-1; LV, left ventricular; KH, Krebs-Henseleit; LVEDP, left ventricular end-diastolic pressure; LVDevP, left ventricular developed pressure; GLUT, glucose transporter; MAP, mitogen-activated protein; MAPKAP, MAP kinase-activated protein kinase; NOx, nitrite/nitrate; NO, nitric oxide; DU, density units.
Address correspondence to: Dr. Richard P. Shannon, Department of Medicine, Allegheny General Hospital, 320 E. North Ave., Pittsburgh, PA 15212. E-mail: rshannon{at}wpahs.org
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Barragan JM, Rodriguez RE, and Blazquez E (1994) Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7–36) amide in rats. Am J Physiol 266: E459–E466.
Barragan JM, Rodriguez RE, Eng J, and Blazquez E (1996) Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 67: 63–68.[CrossRef][Medline]
Bose AK, Mocanu MM, Carr RD, Brand CL, and Yellon DM (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146–151.
Bullock BP, Heller RS, and Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968–2971.[Abstract]
Denton RM and Tavare JM (1995) Does mitogen activated protein kinase have a role in insulin action? The case for and against. Eur J Biochem 227: 597–611.[Medline]
Doyle ME and Egan JM (2001) Glucagon-like peptide-1. Recent Prog Horm Res 56: 377–399.[Abstract]
Drucker DJ (1998) Glucagon-like peptides. Diabetes 47: 159–169.[Abstract]
Egert S, Nguyen N, and Schwaiger M (1999) Myocardial glucose transporter GLUT-1: translocation induced by insulin and ischemia. J Mol Cell Cardiol 31: 1337–1344.[CrossRef][Medline]
Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, and Gutniak M (2003) Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 24: 569–578.[CrossRef][Medline]
Kieffer TJ and Habener JF (1999) The glucagon-like peptides. Endocr Rev 20: 876–913.
McFalls EO, Hou M, Bache RJ, Best A, Marx D, Sikora J, and Ward HB (2004) Activation of p38 MAPK and increased glucose transport in chronic hibernating swine myocardium. Am J Physiol 287: H1328–H1334.
Musi N, Fujii N, Hirshman MF, Ekberg I, Fröberg S, Ljungvist O, Thorell A, and Goodyear LJ (2001) AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 50: 921–927.
Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D, and Shannon RP (2005) Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 312: 303–308.
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen Y-T, and Shannon RP (2004a) rGLP-1 increased myocardial glucose uptake and improved LV performance in conscious dogs with pacing induced dilated cardiomyopathy. Circulation 110: 955–961.
Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, and Shannon RP (2004b) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962–965.
Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, and Shannon RP (2004c) The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61: 297–306.
Nystrom T, Gonon AT, Sjoholm A, and Pernow J (2005) Glucagon-like peptide relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125: 173–177.[CrossRef][Medline]
Nystrom T, Gutniak MK, Zhang, Zhang F, Holst JJ, Ahren B, and Sjoholm A (2004) Effects of glucagons like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol 287: E1209–E1215.
Tada H, Thompson CI, Recchia FA, Loke KE, Ochoa M, Smith CJ, Shesely EG, Kaley G, and Hintze TH (2000) Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. Circ Res 86: 270–279.
Taha C, Tsakiridis T, McCall A, and Klip A (1997) Glucose transport expression in L6 muscle cells: regulation through insulin and stress activated pathways. Am J Physiol 273: E76–E86.
Van Dyke DA, Walters L, Frieswyk D, Kohmeyer D, and Louters LL (2003) Acute effects of troglitizone and nitric oxide on glucose uptake in L929 fibroblasts cells. Life Sci 72: 2321–2327.[Medline]
Vila Petroff MG, Egan JM, Wang X, and Sollott SJ (2001) Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 89: 445–452.
Wei Y and Mojsov S (1996) Distribution of GLP-1 and PACAP receptors in human tissue. Acta Physiol Scand 157: 355–357.[CrossRef][Medline]
Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, et al. (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Investig 110: 43–52.[CrossRef][Medline]
Young LH, Renfu Y, Russell R, Hu X, Caplan M, Ren J, Shulman GI, and Sinusas AJ (1997) Low flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 95: 415–422.
Zhao TC, Taher MM, Valerie KC, and Kukreja RC (2001) p38 triggers late preconditioning elicited by anisomycin in heart: involvement of NF-
B and iNOS. Circ Res 89: 915–922.
This article has been cited by other articles:
|
|
 |
|
  R. K. Campbell and S. Miller New Therapeutic Horizons: Mapping the Future of Glycemic Control With Incretin-based Therapy The Diabetes Educator, September 1, 2009; 35(5): 731 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Abu-Hamdah, A. Rabiee, G. S. Meneilly, R. P. Shannon, D. K. Andersen, and D. Elahi The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1843 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Noyan-Ashraf, M. A. Momen, K. Ban, A.-M. Sadi, Y.-Q. Zhou, A. M. Riazi, L. L. Baggio, R. M. Henkelman, M. Husain, and D. J. Drucker GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice Diabetes, April 1, 2009; 58(4): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sacca Heart Failure as a Multiple Hormonal Deficiency Syndrome Circ Heart Fail, March 1, 2009; 2(2): 151 - 156. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Ayala, D. P. Bracy, F. D. James, B. M. Julien, D. H. Wasserman, and D. J. Drucker The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action Endocrinology, March 1, 2009; 150(3): 1155 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Poornima, S. B. Brown, S. Bhashyam, P. Parikh, H. Bolukoglu, and R. P. Shannon Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure-Prone Rat Circ Heart Fail, September 1, 2008; 1(3): 153 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ban, M. H. Noyan-Ashraf, J. Hoefer, S.-S. Bolz, D. J. Drucker, and M. Husain Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor-Dependent and -Independent Pathways Circulation, May 6, 2008; 117(18): 2340 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
